{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:33:02Z","timestamp":1792290782239,"version":"4.4.0"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:p>CKD mineral and bone disease is a common complication of kidney disease, and it affects the majority of patients with moderate to severe CKD. Recently, prospective studies have shown that measurement of bone mineral density by dual energy x-ray absorptiometry predicts incident fracture, providing nephrologists the ability to risk classify patients for skeletal fragility and targeted antifracture strategies for the first time. Furthermore, an expanding body of literature and anecdotal evidence suggest that pharmacologic agents used to treat osteoporosis in the general population can be safely used in patients with CKD. This review highlights the effects of the Kidney Disease Improving Global Outcomes updates on the management of CKD-associated osteoporosis, discusses recent investigations on the effects of antiosteoporotic agents in patients with CKD, and provides an overview of novel antiosteoporosis agents and the potential challenges related to their use in CKD.<\/jats:p>","DOI":"10.2215\/cjn.11031017","type":"journal-article","created":{"date-parts":[[2018,2,27]],"date-time":"2018-02-27T20:35:18Z","timestamp":1519763718000},"page":"962-969","source":"Crossref","is-referenced-by-count":117,"title":["Management of Osteoporosis in CKD"],"prefix":"10.2215","volume":"13","author":[{"given":"Pascale","family":"Khairallah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8870-1896","authenticated-orcid":false,"given":"Thomas L.","family":"Nickolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2018,2,27]]},"reference":[{"key":"B1-20230813","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1046\/j.1523-1755.2000.00178.x","article-title":"Increased risk of hip fracture among patients with end-stage renal disease","volume":"58","author":"Alem","year":"2000","journal-title":"Kidney Int"},{"key":"B2-20230813","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/jbmr.2862","article-title":"Hip fracture in patients ith non-dialysis-requiring chronic kidney disease","volume":"31","author":"Kim","year":"2016","journal-title":"J Bone Miner Res"},{"key":"B3-20230813","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","article-title":"Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) guideline update: What\u2019s changed and why it matters","volume":"92","author":"Ketteler","year":"2017","journal-title":"Kidney Int"},{"key":"B4-20230813","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.2215\/CJN.12871211","article-title":"Bone mineral density and fracture risk in older individuals with CKD","volume":"7","author":"Yenchek","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"B5-20230813","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfr317","article-title":"Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients--a single-center cohort study","volume":"27","author":"Iimori","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"B6-20230813","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/jbmr.2406","article-title":"Bone mineral density predicts fractures in chronic kidney disease","volume":"30","author":"West","year":"2015","journal-title":"J Bone Miner Res"},{"key":"B7-20230813","doi-asserted-by":"crossref","first-page":"646","DOI":"10.2215\/CJN.06040614","article-title":"Comparison of fracture risk prediction among individuals with reduced and normal kidney function","volume":"10","author":"Naylor","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"B8-20230813","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s00198-003-1435-y","article-title":"Relationship between age, renal function and bone mineral density in the US population","volume":"14","author":"Klawansky","year":"2003","journal-title":"Osteoporos Int"},{"key":"B9-20230813","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1681\/ASN.2005111194","article-title":"Relationship between moderate to severe kidney disease and hip fracture in the United States","volume":"17","author":"Nickolas","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"B10-20230813","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1053\/j.ajkd.2013.02.368","article-title":"Trends in hip fracture rates in US hemodialysis patients, 1993-2010","volume":"62","author":"Arneson","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"B11-20230813","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.2215\/CJN.10901012","article-title":"Temporal trends in the incidence, treatment, and outcomes of hip fracture in older patients initiating dialysis in the United States","volume":"8","author":"Nair","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"B12-20230813","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/ndt\/gft352","article-title":"Increased bone fractures among elderly United States hemodialysis patients","volume":"29","author":"Wagner","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"B13-20230813","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1681\/ASN.2012090916","article-title":"Temporal trends in fracture rates and postdischarge outcomes among hemodialysis patients","volume":"24","author":"Beaubrun","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"B14-20230813","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2215\/CJN.03940510","article-title":"Vitamin D supplementation in chronic kidney disease: A systematic review and meta-analysis of observational studies and randomized controlled trials","volume":"6","author":"Kandula","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"B15-20230813","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1111\/j.1523-1755.2005.00603.x","article-title":"25-Hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy","volume":"68","author":"Coen","year":"2005","journal-title":"Kidney Int"},{"key":"B16-20230813","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1053\/j.ajkd.2009.06.004","article-title":"Benefits and harms of phosphate binders in CKD: A systematic review of randomized controlled trials","volume":"54","author":"Navaneethan","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"B17-20230813","doi-asserted-by":"crossref","first-page":"232","DOI":"10.2215\/CJN.06800615","article-title":"Sevelamer versus calcium-based binders for treatment of hyperphosphatemia in CKD: A meta-analysis of randomized controlled trials","volume":"11","author":"Patel","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"B18-20230813","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.2215\/CJN.10661013","article-title":"A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD","volume":"9","author":"Coyne","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"B19-20230813","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1681\/ASN.2014040414","article-title":"Effects of cinacalcet on fracture events in patients receiving hemodialysis: The EVOLVE trial","volume":"26","author":"Moe","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B20-20230813","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s10157-012-0665-8","article-title":"Effects of cinacalcet on bone mineral density and bone markers in hemodialysis patients with secondary hyperparathyroidism","volume":"17","author":"Tsuruta","year":"2013","journal-title":"Clin Exp Nephrol"},{"key":"B21-20230813","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/ki.2014.349","article-title":"Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism","volume":"87","author":"Behets","year":"2015","journal-title":"Kidney Int"},{"key":"B22-20230813","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1093\/ndt\/gfr620","article-title":"Tests of neuromuscular function are associated with fractures in patients with chronic kidney disease","volume":"27","author":"West","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"B23-20230813","doi-asserted-by":"crossref","first-page":"801","DOI":"10.7326\/0003-4819-128-10-199805150-00002","article-title":"Protein supplements increase serum insulin-like growth factor-I levels and attenuate proximal femur bone loss in patients with recent hip fracture. A randomized, double-blind, placebo-controlled trial","volume":"128","author":"Sch\u00fcrch","year":"1998","journal-title":"Ann Intern Med"},{"key":"B24-20230813","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1001\/jama.2009.1462","article-title":"Incidence and mortality of hip fractures in the United States","volume":"302","author":"Brauer","year":"2009","journal-title":"JAMA"},{"key":"B25-20230813","doi-asserted-by":"crossref","first-page":"649","DOI":"10.7326\/M16-2752","article-title":"Benefits and harms of osteoporosis medications in patients with chronic kidney disease: A systematic review and meta-analysis","volume":"166","author":"Wilson","year":"2017","journal-title":"Ann Intern Med"},{"key":"B26-20230813","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1359\/JBMR.050817","article-title":"Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: A pooled analysis of nine clinical trials","volume":"20","author":"Miller","year":"2005","journal-title":"J Bone Miner Res"},{"key":"B27-20230813","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1359\/jbmr.070112","article-title":"Alendronate treatment in women with normal to severely impaired renal function: An analysis of the fracture intervention trial","volume":"22","author":"Jamal","year":"2007","journal-title":"J Bone Miner Res"},{"key":"B28-20230813","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12882-017-0478-9","article-title":"Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: Post-hoc analysis of data from the risedronate phase III clinical trials","volume":"18","author":"Shigematsu","year":"2017","journal-title":"BMC Nephrol"},{"key":"B29-20230813","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1053\/j.ajkd.2009.12.039","article-title":"Effect of alendronate on vascular calcification in CKD stages 3 and 4: A pilot randomized controlled trial","volume":"56","author":"Toussaint","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"B30-20230813","first-page":"510","article-title":"Treatment of reduced bone density with ibandronate in dialysis patients","volume":"21","author":"Bergner","year":"2008","journal-title":"J Nephrol"},{"key":"B31-20230813","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s00198-016-3861-7","article-title":"Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia","volume":"28","author":"Ota","year":"2017","journal-title":"Osteoporos Int"},{"key":"B32-20230813","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/jbmr.403","article-title":"Effects of denosumab on fracture and bone mineral density by level of kidney function","volume":"26","author":"Jamal","year":"2011","journal-title":"J Bone Miner Res"},{"key":"B33-20230813","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"B34-20230813","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/jbmr.1613","article-title":"A single-dose study of denosumab in patients with various degrees of renal impairment","volume":"27","author":"Block","year":"2012","journal-title":"J Bone Miner Res"},{"key":"B35-20230813","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1210\/jc.2014-1154","article-title":"An open-label, prospective pilot clinical study of denosumab for severe hyperparathyroidism in patients with low bone mass undergoing dialysis","volume":"99","author":"Chen","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B36-20230813","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40620-016-0334-1","article-title":"Safety and efficacy of denosumab in osteoporotic hemodialysed patients","volume":"30","author":"Festuccia","year":"2017","journal-title":"J Nephrol"},{"key":"B37-20230813","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00223-005-0161-1","article-title":"The receptor activator of nuclear factor-kappaB ligand inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism","volume":"78","author":"Padagas","year":"2006","journal-title":"Calcif Tissue Int"},{"key":"B38-20230813","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00198-006-0189-8","article-title":"Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment","volume":"18","author":"Miller","year":"2007","journal-title":"Osteoporos Int"},{"key":"B39-20230813","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000316708","article-title":"Treatment of hemodialysis-associated adynamic bone disease with teriparatide (PTH1-34): A pilot study","volume":"33","author":"Cejka","year":"2010","journal-title":"Kidney Blood Press Res"},{"key":"B40-20230813","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00198-015-3377-6","article-title":"Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: A prospective study","volume":"27","author":"Sumida","year":"2016","journal-title":"Osteoporos Int"},{"key":"B41-20230813","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00223-016-0171-1","article-title":"Six weeks of daily Abaloparatide treatment increased vertebral and femoral bone mineral density, microarchitecture and strength in ovariectomized osteopenic rats","volume":"99","author":"Bahar","year":"2016","journal-title":"Calcif Tissue Int"},{"key":"B42-20230813","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1210\/jc.2014-3718","article-title":"Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis","volume":"100","author":"Leder","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B43-20230813","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of Abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: A randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"key":"B44-20230813","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.bone.2016.11.004","article-title":"Effects of Abaloparatide-SC (BA058) on bone histology and histomorphometry: The ACTIVE phase 3 trial","volume":"97","author":"Moreira","year":"2016","journal-title":"Bone"},{"key":"B45-20230813","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"key":"B46-20230813","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or Alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"key":"B47-20230813","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"key":"B48-20230813","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: A randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"key":"B49-20230813","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1074\/mcp.M110.001693","article-title":"Proteomics characterization of extracellular space components in the human aorta","volume":"9","author":"Didangelos","year":"2010","journal-title":"Mol Cell Proteomics"},{"key":"B50-20230813","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/1471-2369-14-219","article-title":"Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: A cross-sectional study","volume":"14","author":"Brandenburg","year":"2013","journal-title":"BMC Nephrol"},{"key":"B51-20230813","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","article-title":"National Osteoporosis Foundation: Clinician's guide to prevention and treatment of osteoporosis","volume":"25","author":"Cosman","year":"2014","journal-title":"Osteoporos Int"},{"key":"B52-20230813","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0025-6196(11)62214-3","article-title":"Secondary causes of osteoporosis","volume":"77","author":"Fitzpatrick","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"B53-20230813","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/ki.2008.60","article-title":"Adynamic bone in patients with chronic kidney disease","volume":"73","author":"Andress","year":"2008","journal-title":"Kidney Int"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201806000-00025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:41:02Z","timestamp":1786369262000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201806000-00025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,27]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.11031017","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,27]]}}}